BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1963 related articles for article (PubMed ID: 8796771)

  • 1. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal serum screening for birth defects: results of a Connecticut regional program.
    Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
    Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
    Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
    Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Noninvasive serum test for prenatal detection of Down syndrome, other chromosome abnormalities and open neural tube defects--a prospective study].
    Zwahr C; Voss P; Kistner G
    Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):355-61. PubMed ID: 7522195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal screening for Down's syndrome with use of maternal serum markers.
    Haddow JE; Palomaki GE; Knight GJ; Williams J; Pulkkinen A; Canick JA; Saller DN; Bowers GB
    N Engl J Med; 1992 Aug; 327(9):588-93. PubMed ID: 1379344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Screening by maternal serum markers for Down's syndrome].
    Liu JT; Hao N; Sun NH; Wang FY; Xu YH; Gai MY; Bian XM; Yang JQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):156-9. PubMed ID: 12905710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trisomy-21 screening using AFPplus in the eastern part of Switzerland].
    Zimmermann R; Schmid W; Binkert F; Achermann J; Huch R; Huch A
    Schweiz Med Wochenschr; 1995 Jul; 125(26):1286-93. PubMed ID: 7541552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal serum screening for aneuploid pregnancy by alpha-fetoprotein, hCG, and unconjugated estriol.
    Heyl PS; Miller W; Canick JA
    Obstet Gynecol; 1990 Dec; 76(6):1025-31. PubMed ID: 1700348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
    Wald NJ; Watt HC
    Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal biochemical screening for Down's syndrome and neural tube defects.
    Wald NJ; Kennard A
    Curr Opin Obstet Gynecol; 1992 Apr; 4(2):302-7. PubMed ID: 1373963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down's syndrome risk estimates demonstrate considerable heterogeneity despite homogeneity of input.
    Reynolds T; Ellis A; Jones R
    Ann Clin Biochem; 2004 Nov; 41(Pt 6):464-8. PubMed ID: 15588435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
    N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 99.